Degradation of signaling proteins is one of the most powerful tumor suppressive mechanisms by which a cell can control its own growth. Here, we identify RHOA as the molecular target by which autophagy maintains genomic stability. Specifically, inhibition of autophagosome degradation by the loss of the vATPase a3 (TCIRG1) subunit is sufficient to induce aneuploidy. Underlying this phenotype, active RHOA is sequestered via p62 (SQSTM1) within autolysosomes, and fails to localize to the plasma membrane or to the spindle midbody. Conversely, inhibition of autophagosome formation by ATG5 shRNA dramatically increases localization of active RHOA at the midbody, followed by diffusion to the flanking zones. As a result, all of the approaches we examined that compromise autophagy (irrespective of the defect: autophagosome formation, sequestration or degradation) drive cytokinesis failure, multinucleation, and aneuploidy, processes that directly have an impact upon cancer progression. Consistently, we report a positive correlation between autophagy defects and the higher expression of RHOA in human lung carcinoma. We therefore propose that autophagy may act in part as a safeguard mechanism that degrades and thereby maintains the appropriate level of active RHOA at the midbody for faithful completion of cytokinesis and genome inheritance.
Introduction
Cells are faced with the tasks of dividing, of keeping the genome intact, and even of dying when appropriate. At their heart, these cell fates are dictated by tumor-suppressor mechanisms. One such mechanism is autophagy, which is commonly mutated or downregulated in human cancers (1) . Indeed, the essential autophagy gene BECN1 is deleted or mutated in 40 to 75% of breast, ovarian, colon and prostate cancers. Consistently, the notion that autophagy suppresses tumor development came from the demonstration that allelic loss of Becn1 predisposes mice to lymphomas, hepatocellular carcinomas, and lung carcinomas (2, 3) . Likewise, defects in other autophagy genes (Atg4c, Atg5, Uvrag, Ambra1, and Bif-1/Sh3glb1) render cells or mice tumor prone (4) (5) (6) (7) (8) .
Physiologically, autophagy ensures in all cell types the turnover of all organelles and most longlived proteins by a pathway, which begins with the formation of a double-membrane compartment, termed a "phagophore" that sequesters them. The phagophore expands into a completed vesicle, an "autophagosome", and subsequently, the autophagosome rapidly fuses with a lysosome to become an "autolysosome" where the content is finally degraded. Originally identified as a housekeeping process, emerging data suggest that constitutive autophagy (i.e., under nutrient-rich conditions) might also fight cancer by limiting inflammation (9) , facilitating senescence (10) or clearing signaling proteins (11) .
Likewise, recent studies reveal that both BECN1 and ATG5 function as 'guardians' of cellular genome.
Epithelial cells with loss of Becn1 or Atg5, display gene amplification, and aneuploidy (7, 8) . In support, activation of autophagy was demonstrated to reduce genomic instability within hepatocarcinoma cells (12) . However, despite the importance of aneuploidy in cancer development (13, 14) , the mechanisms underlying how autophagy deficiency compromises genomic stability are still unknown.
To address this issue, we explored the possibility that signaling proteins essential for cell growth might be degraded by autophagy. Whereas significant advances have been made in the discovery of Author Manuscript Published OnlineFirst on May 23, 2013 ; DOI: 10.1158/0008-5472. autophagy machinery, less is known about the nature of the autophagy substrates. Therefore, a key feature of our strategy was to inhibit the autophagy pathway at the degradation step, in order to achieve sequestration and accumulation of substrates within autolysosomal structures (Fig. S1A) . 
Materials and Methods

Cell culture and treatments
To inhibit the maturation of autophagosomes into degradative autolysosomes, renal cells derived from proximal convoluted tubules of wild-type (WT, a3 +/+ ) or the lysosomal v-ATPase a3/TCIRG1-null mice (a3 −/− ) were isolated and immortalized with the pSV3 neo vector. The renal epithelial cell lines that do or do not express a3 were referred to as WT and a3 −/− cells, respectively. As controls, cells were stimulated with an inhibitor of v-ATPase activity, bafilomycin A1 (100 nM, bafA1; Sigma); or a weak base that raises intralysosomal pH, chloroquine (100 μM, CQ; Sigma). Alternatively, the formation of autophagosomes was inhibited at the initiation step by Atg5 or Atg7 short hairpin RNA (shRNA). As a further control, we analyzed the phenotype of Atg5 KO MEFs (provided by N. Mizushima) (15) , and ATG5-depleted A549 lung epithelial cells. We also prevented the sequestration of autophagy substrates within the autophagic vesicles by p62 shRNA. For details on cell culture and shRNA sequences see supplemental information.
Clinical samples
Primary NSCLC (pairs of pathological and control tissues from the same patient) were obtained from patients in Nice (France) and collected by the Tumor Biobank of Nice Hospital (Nice CHU, agreement 2010-06).
Analysis of autophagy
The activity of the autophagy pathway was monitored by four hallmarks: i) the formation of autophagic vesicles; and the degradation of three well-established autophagy substrates: ii) membrane-associated LC3-II; iii) p62/SQSTM1; and iv) long-lived proteins. 
Time-lapse video microscopy
For monitoring cell progression through mitosis, exponentially growing cells cultured in complete growth medium were imaged every 5 min during 18 h on an inverted microscope (Carl Zeiss) equipped with a CO 2 -equilibrated chamber.
Analysis of the RHOA pathway
The activity of RHOA pathway was monitored by i) the levels of active GTP-bound RHO (RHOTEKIN RHO Binding Domain Pull-down and ELISA-based G-LISA assays, Cytoskeleton Inc.); ii) the recruitment of RHOA to membranes; and iii) the downstream phosphorylation of myosin regulatory light chain (P-MLC) and reticulation of ACTIN cytoskeleton.
RHOA immunoprecipitation
Cells were lysed in RIPA and RHOA was immunoprecipitated with anti-RHOA antibody followed by western blotting with anti-ubiquitin, anti-p62, anti-LC3 and anti-RHOA antibodies. 
RHOA stability
Results
The V-ATPase a3-dependent autophagy defect is characterized by the formation of giant multinucleate cells
To gain a deeper insight into the role of autophagy, we established cell-lines from v-ATPase a3/TCIRG1-null mice (16) . PCT (proximal convoluted tubule) cells were chosen as they express the highest level of vATPase (17) ; the a3 subunit is localized in the lysosomal limiting membrane (18) . In agreement with the other reported defect of v-ATPase (19, 20) , we show that the a3 loss increased autophagy sequestration and simultaneously impaired autophagic degradation, as evidenced by the accumulation of ATG12-ATG5 conjugate, of autolysosomes and of autophagic substrates (long-lived proteins, LC3-II, and p62) ( Fig. 1A and S1B). In contrast, a3-null cells seemed to have functionally intact proteasomes (Fig. S1C) .
Remarkably, this a3-dependent autophagy defect was characterized by an increase in cell size and a flattened morphology with the accumulation of vesicles and nuclei (Fig. 1B-C) , supporting the importance of autophagy in maintaining cell size (21, 22) . By using different approaches, we excluded a role for senescence as a cause of enlarged morphology (Fig. S2) did not observe cell-cell fusion, cell engulfment and endoreplication during live-cell imaging (n=200).
Thus, impairment of cytokinesis at the membrane abscission step was the key event responsible for the formation of multinucleate a3 −/− cells.
The inhibition of autophagy degradation by v-ATPase a3 loss stabilizes RHOA-
GTP within autolysosomes
We then explored which signaling proteins might be degraded by autophagy and could underlie this phenotype. One candidate was the small GTPase RHOA, that dictates cell shape and completion of cytokinesis via F-ACTIN reticulation (23) . In this regard, a striking hallmark of a3 −/− cells was a dramatic remodeling of ACTIN cytoskeleton with the loss of stress fibers and the formation of ACTIN patches ( exchange factors (GEFs) that activate them, the GTPase-activating proteins (GAPs) that inactivate them, and the guanine nucleotide-dissociation inhibitors (GDIs) that maintain RHO inactive within the cytoplasm (23) . Exciting findings have revealed that RHO GTPases, their upstream regulators and downstream targets might also be subjected to irreversible proteasome-dependent degradation (24) (25) (26) (27) (28) (29) (30) (31) (32) .
Instead of proteasome, however, we determined that active RHOA was constitutively maintained at low levels by autophagy. Indeed, the active RHOA was barely detected at the plasma membrane of A role for autophagy in controling RHOA-GTP level was then suggested by the shRNA-mediated inhibition of autophagosome formation: expression of Atg5 shRNA increased the localization of active RHOA at the plasma membrane of a3 −/− cells, which allowed ACTIN polymerization into filaments (Fig.   3D ). Consistently, the Atg5 shRNA-transduced a3 −/− cells displayed a smaller size and tight cohesion within the colony (Fig. 3D) . Importantly, the control of RHOA by autophagy was remarkably specific, as the related GTPase RAC (Fig. S4E) , as well as the RHOA regulator, RHOGDI, were not affected (Fig. 3C ).
Together, these data highly suggest a working model in which autophagy might sequester and degrade active RHOA. Inhibition of v-ATPase by a3 loss would stabilize RHOA-GTP within autolysosomal structures, protecting it from autophagy degradation, and at the same time this would preclude reticulation of ACTIN cytoskeleton (Fig. S1A ). p62-dependent autophagy specifically degrades active RHOA As proof-of-concept, pharmacological inhibition of autophagy degradation by bafA1 or chloroquine (CQ) treatment similarly increased the levels of membrane-bound RHOA together with the autophagy substrates LC3-II and p62 (Fig. S5 ). This occurred in multiple cell types, including fibroblast, kidney, and lung epithelial cells (Fig. S5A) . In contrast, impairment of proteasome by MG132 failed to alter the levels of the membrane-bound RHOA in every cell line tested (Fig. S5A) . As expected, all features of a3 −/− cells (i.e., RHOA autolysosomal recruitment, F-ACTIN depolymerization, and increased cell size) were mimicked by bafA1, but not MG132 treatment, further supporting the model that activity of the RHOA pathway can be controlled by the autophagy-lysosome pathway ( Fig. S5B-C) . Consistently, the active, but not inactive, RHOA mutants were long-lived proteins selectively degraded by autophagy (Fig. 4) . At this stage, it was of interest to address how autophagy may specifically targets the active RHOA. One adaptor by which autophagy acquires specificity is p62 (SQSTM1) that targets ubiquitinated substrates to the autophagy machinery (33) . Of interest, p62 appears as a prime candidate for regulating RHOA as it is the sole autophagy adaptor involved in cell mitosis (34) , cell spreading (35) and tumor growth (36) (37) (38) . We observed that p62 not only co-immunoprecipitated ( Fig. 4C ) and co-localized ( Fig.   4D ) with ubiquitinated RHOA and LC3-II in CQ-treated cells but also was essential in the selective clearance of active RHOA by autophagy ( Fig. 4B and D) . Upon p62 silencing and CQ treatment, autophagosomes formed normally (as evidenced by LC3-II conversion, Fig. S6A ), but the autophagic (Fig. 4D) and degradation (Fig. 4B) active RHOA was at the equatorial furrow and was instead sequestered within autolysosomes, close to the midbody (Fig. 5A ), likely as a result of increased sequestration. Inversely, when we blocked autophagosome formation by ATG5 shRNA (Fig. S6A) , RHOA was highly enriched at the equatorial furrow of cytokinetic A549 lung cancer cells ( Fig. 5B and S7A) . Notably, the RHO activity zone in ATG5-depleted cells was three times as wide and bright as in controls (control shRNA = 3.7 ± 0.8 μm; ATG5 shRNA = 11.4 ± 2.6 μm; mean ± SD, Fig. 5C-D) . Outside the cell equator, RHOA activity was also abnormally high at the cell cortex ( Fig. 5B and S7) . Accordingly, Atg5 knockdown in mouse embryonic fibroblasts (Fig. 5E) , and ATG7 or p62 depletion in A549 cells (Fig. S6 ) faithfully recapitulated the same phenotype with regard to the RHOA pathway. Likewise, closer examination indicated that the upstream regulators required for narrowed activation of RHOA such as the kinesin MKLP1, the RHOA GEF ECT2 and spindle microtubules concentrated at the midbody of cytokinetic cells (Fig. S8A-B ) (43) . It is also highly likely that the loss of 
ATG5 would creates defects in the generation and the delivery of new membranes to the cleavage furrow, a process that is central to cytokinesis. As shown in Figure S8C , the delivery of endosomes to the midbody appeared not to be affected by ATG5 depletion: the endosomes were delivered to the cleavage furrow and clustered on either side of midbody of ATG5-depleted cells, as observed in control cells. By contrast, ATG5-depleted cells exhibited in addition to RHOA a broader distribution of downstream F-ACTIN that triggers the formation of actomyosin ring (Fig. S7B) . Our data therefore suggest that the degradation of RHOA by autophagy may function as a key, but hitherto uncharacterized, mechanism concentrating active RHOA at midbody.
Autophagy defects fuel chromosomal instability in lung cancer cells
Considering the apparent connection between autophagy and RHOA, a key issue is how defects in autophagy might affect cell behavior in a way relevant for cancer progression. Maintaining the appropriate amount of active RHOA at midbody is critical for faithful cytokinesis as it dictates the position, the formation and the contraction of actomyosin ring (42, 44) . If our model were correct, one would expect that the inhibition of autophagy sequestration in autophagy-competent A549 tumor cells would be sufficient to disturb cytokinesis and thereby drive the genomic instability required for tumor progression. As shown in Figure 6 , in control A549 cells, the clustering of RHOA in a narrow zone resulted in the formation of a unique and compact ring whose position and size remained constant throughout furrow ingression (Fig. 6A-B, upper panels) . As a result, control cells successfully completed cytokinesis (Movie S6). Without functional autophagy, the subsequent hyperactivation of RHOA zone would jeopardize the assembly of an efficient contractile ring, as expected from the cytokinesis defects observed for active RHOA mutants (Fig. S4C) . Indeed, ATG5-depleted A549 cells progressed through mitosis until the furrow started to constrict, then 52% of the cells demonstrated unstable and loose furrowing that suddenly fell apart, reformed and constricted more slowly than control furrows, delaying cytokinesis completion (Fig. 6A-B , lower panels, Movie S6). As result of cytokinesis failure, these autophagy compromises (ATG5 shRNA and p62 shRNA) were sufficient to increase the percentage of cells with multiple nuclei (Fig. 6C) , and the frequency of chromosomal gains and losses in nearly all of the chromosomes (Fig. 6D) , one hallmark of aggressive cancer. Together, these findings highly suggested that autophagy may act in part as a master safeguard mechanism of active RHOA localization during cytokinesis for faithful genome inheritance.
Overexpression of RHOA is correlated with autophagy defects in lung carcinomas
The biochemical, cellular, and genomic changes (increased RHOA activity, increased cellular sizes, and aneuploidy) we consistently observed herein following autophagy inhibition (irrespective of particular autophagy defects) are noteworthy because they accompany the onset and progression of cancers.
RHOA overexpression has been observed in many aggressive cancers, such as breast, colon, prostate, and lung cancers, but has been attributed largely to increased RHOA transcription (45) . Consistent with a role of autophagy in RHOA degradation, we found that RHOA, together with p62 and LC3-II were overexpressed in late stages of non-small cell lung cancers (NSCLC; T; pTNM stage IIIA), compared to normal epithelia (N) and stage I adenocarcinomas (Fig. 7A-B ). An impaired autophagic degradation rather than an increased transcription was correlated with RHOA overexpression, as the levels of RHOA expression and activity increased progressively with the accumulation of the autophagy substrates p62 and LC3-II (Fig. 7A) , and no significant changes in RHOA mRNA expression were measured (Fig. 7A, right   panel) . Of interest, the inactivation of autophagy and the subsequent RHOA upregulation were not early events, but instead were late events in the progression of lung cancer, when these cancers acquire a more genomic instability. All tumor cells positive for p62 were also RHOA-positive (Fig. 7B ). p62 overexpression, as a readout of an autophagy defect, was associated with a reduced or absent RHOA The regulation of RHOA is unique in that it involves GEF, GAP, and GDI proteins, along with the proteasome (47) and autophagy. Depending on its activation state, we provide the first lines of evidence that RHOA used distinct routes for degradation: while the proteasome degraded the cytosolic and inactive forms, the autophagy pathway specifically degraded the membrane-associated and active pool of RHOA. This is consistent with the recently reported degradation of two constitutively active RHO, RHOH and RHOB, within lysosomes (48, 49 ) and the redistribution of active RHOA to undefined 
perinuclear localization after treatment of enterocytes with an autophagy inducer, LPS (50) . We therefore propose that autophagy may act as a tumor suppressor pathway in part by turning off RHOA activation (Fig. 7C ). In this model, the remarkable dynamics of autophagy together with its integration of extracellular cues might dictate the time and place where a RHOA is active, and able to interact with its downstream substrates. Accordingly, we reported the targeting of autolysosomes at midbody during cytokinesis, the same subcellular and temporal localizations where RHOA should be controlled.
Therefore, autophagy might be critical for localized degradation of active RHOA at midbody and thereby proper ACTIN dynamics during accurate completion of cytokinesis and faithful genome inheritance.
The development of a cancer depends on the ability of tumor cells to acquire growth advantages. Whatever the mutations, deletions, and epigenetic silencing of autophagy genes, our findings provide new information on how autophagy defects can drive tumor progression through deregulation of RHOA pathway. As autophagy is commonly downregulated in cancers (1) where RHOA is overexpressed (47) , this new paradigm may be a general mechanism for the acquisition of aneuploidy and progression of human cancer cells. Virtually all control cells showed normal compact furrowing during cytokinesis (85%; n=100, upper inset), whereas the majority (52%; P= 2. 8 10 -19 ; n=50) of telophase ATG5-depleted cells exhibited unstable and loose furrowing. The black arrowheads indicate ectopic furrows and the bar marks the width of the equatorial furrow. Table S1 ) versus normal peritumoral tissues (N, normal) using the indicated antibodies. p62 serves as a positive control for autophagy impairment (36) , and ACTIN as a loading control. Similar RHOA mRNA levels in tumor and normal tissues (right panel, not statistically significant).
B, Immunohistochemical staining revealed a high overexpression of RHOA and p62 in late stages of NSCLC. In line with a3 −/− cell results (Fig. 3) , the defect in lung cancer samples was a defect in autophagosome degradation with the concomitant accumulation of the three autophagy substrates LC3, p62, and active RHOA (RHOA recruitment to intracellular cell membranes; and downstream Ê-MLC).
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